The Hindu·2 min read·medium

DRI searches Cipla’s Mumbai office and Bhiwandi depot over imported drug classification

P
PTI
DRI searches Cipla’s Mumbai office and Bhiwandi depot over imported drug classification
✦AI Summary

The Directorate of Revenue Intelligence conducted searches at Cipla's Mumbai office and Bhiwandi depot regarding the classification of an imported pharmaceutical product. Cipla stated the proceedings will not have a material impact on its operations and is cooperating with authorities.

Why it matters

Regulatory scrutiny of pharmaceutical import classifications can impact supply chains and compliance costs for major drug manufacturers.

✦Dive DeeperCreate a free account to unlock

New Delhi The Directorate of Revenue Intelligence (DRI), Mumbai zonal unit, has conducted searches at pharmaceutical company Cipla’s office in Vikhroli and its depot in Bhiwandi, Thane, over the classification or exemption of an imported finished pharmaceutical product. The searches were conducted on Monday under Section 105 of the Customs Act, 1962. Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
businesshealth
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in